Alterity Therapeutics Limited
ATHE | NASDAQ
$4
+$0.22 (+5.82%)
Sep 22, 2026, 1:40 PM ET · Market open
Fiscal Year Period Ending | FY 2026 Jun 29, 2026 | FY 2025 Jun 29, 2025 | FY 2024 Jun 29, 2024 | FY 2023 Jun 29, 2023 | FY 2022 Jun 29, 2022 | FY 2021 Jun 29, 2021 |
|---|---|---|---|---|---|---|
Revenue | n/a | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
Cost of Revenue | 113.01K | 127.52K | 214.3K | 285.07K | 364.67K | 360.03K |
Gross Profit | -113.01K | 5.31M | 3.8M | 3.63M | 4.76M | 3.98M |
Operating Income | -27.8M | -14.57M | -19.6M | -14.64M | -15.5M | -15.18M |
Interest Income | 1.68M | 446.29K | 268.42K | 16.44K | 2.5K | 20.68K |
Pretax Income | -26.31M | -12.08M | -19.08M | -13.7M | -12.78M | -15.31M |
Net Income | -22.89M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Selling & General & Admin | 10.44M | 5.48M | 4.76M | 5.04M | 5.51M | 6.87M |
Research & Development | 17.24M | 14.4M | 18.64M | 13.2M | 14.75M | 12.28M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 27.69M | 19.89M | 23.41M | 18.24M | 20.26M | 19.16M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | -9.67K | 51.48K | 79.33K | 21.81K |
Cost & Expenses | 27.8M | 20.01M | 23.62M | 18.52M | 20.62M | 19.52M |
Income Tax Expense | -3.42M | 68.06K | 46.09K | 104.46K | 70.01K | -3.08M |
Shares Outstanding (Basic) | 17.54M | 10.66M | 6.08M | 4.05M | 4.01M | 2.83M |
Shares Outstanding (Diluted) | 17.54M | 10.66M | 6.08M | 4.05M | 4.01M | 2.83M |
EPS (Basic) | -1.32 | -1.14 | -3.12 | -3.42 | -3.18 | -5.40 |
EPS (Diluted) | -1.32 | -1.14 | -3.12 | -3.42 | -3.18 | -5.40 |
EBITDA | -27.69M | -14.63M | -19.57M | -14.6M | -17.39M | -15.16M |
EBIT | -27.8M | -14.66M | -19.61M | -14.64M | -17.45M | -15.18M |
Depreciation & Amortization | 113.01K | 28.31K | 35.34K | 37.85K | 54.21K | 18.66K |
Add to Watchlist
Select watchlists to add or remove ATHE